Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.
Another site in the U.S. has begun recruiting for a Phase II clinical trial of Northwest Biotherapeutics' DCVax-L personalized brain cancer vaccine for the treatment of glioblastoma multiforme.
After a two-year postponement, Northwest Biotherapeutics has started enrolling patients in a 240-patient clinical study of DCVax, its brain cancer vaccine. Previously, the trial had 33 patients and
Northwest Biotherapeutics startled investors with the news that it has only $1.1 million of cash on hand--enough to fund operations through September. And assurances that the developer is in talks
Researchers are touting the early results from a study of a new brain cancer vaccine that combines protein antigens extracted from a patient's tumor and matches them with white cells also drawn from